# Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis

> **NCT03546816** · PHASE3 · COMPLETED · sponsor: **Vyne Therapeutics Inc.** · enrollment: 285 (actual)

## Conditions studied

- Pruritus
- Prurigo Nodularis

## Interventions

- **DRUG:** 5mg Serlopitant Tablets
- **DRUG:** Placebo Tablets

## Key facts

- **NCT ID:** NCT03546816
- **Lead sponsor:** Vyne Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-02
- **Primary completion:** 2020-01-14
- **Final completion:** 2020-02-14
- **Target enrollment:** 285 (ACTUAL)
- **Last updated:** 2021-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03546816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03546816, "Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03546816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*